Newsroom

FRANCFORT, Allemagne et GANZHOU, Chine--(BUSINESS WIRE)--Merz Therapeutics GmbH et Jiangxi Kvvit Pharmaceutical Co. Ltd. ont annoncé aujourd’hui avoir conclu un accord exclusif de licence et de collaboration concernant INBRIJA® (poudre pour inhalation de lévodopa) et son dispositif d’inhalation exclusif pour le traitement intermittent des fluctuations motrices épisodiques (épisodes OFF) chez les patients adultes atteints de la maladie de Parkinson (MP) traités par un inhibiteur de la lévodopa/d...

POZNAN, Polonia--(BUSINESS WIRE)--La Universidad Tecnológica de Poznan (PUT) ha puesto en marcha su primer ordenador cuántico instalado in situ, implantado por IQM Quantum Computers, con el fin de promover la educación y la investigación científica en el ámbito de las tecnologías cuánticas. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versió...

FRANKFURT, Deuschland & GANZHOU, China--(BUSINESS WIRE)--Die Merz Therapeutics GmbH und die Jiangxi Kvvit Pharmaceutical Co. Ltd. gaben heute bekannt, dass die Unternehmen eine exklusive Lizenz- und Kooperationsvereinbarung bezüglich INBRIJA® (Levodopa-Inhalationspulver) und dessen proprietärem Inhalationsgerät zur intermittierenden Behandlung episodischer motorischer Fluktuationen (OFF-Episoden) bei erwachsenen Patienten mit Parkinson-Krankheit (PD), die mit einem Levodopa/Dopa-Decarboxylase-H...

HOUSTON--(BUSINESS WIRE)--SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approxim...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Lockheed Martin Corporation (NYSE: LMT) (“Lockheed” or the “Company”).Beginning in early 2024, the Company publicly represented that it had disciplined bidding practices and adequate oversight of its classified defense contracts. However, in three successive disclosures —...

REDMOND, Wash.--(BUSINESS WIRE)--Starcloud has signed a contract with SpaceX’s Starlink to integrate its mini laser terminals. The deal covers 50+ Starlink Mini Lasers across 25+ satellites with the first hardware expected on orbit within one year. Each of the Starcloud satellites will carry two Starlink Mini Laser terminals, the same laser crosslink technology that SpaceX developed for its Starlink constellation, providing up to 25 Gbps of continuous intersatellite connectivity at distances up...

SANTA CLARA, Calif. & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the most secure hardware-backed passkey, the YubiKey, today announced the certification of the next generation of its YubiKey 5 FIPS Series – now FIPS 140-3 validated with Certificate #5291. Published by the National Institute of Standards and Technology (NIST), this milestone represents the latest evolution in cryptographic module...

SANTA CLARA, Calif. & STOCKHOLM--(BUSINESS WIRE)--Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the most secure hardware-backed passkey, the YubiKey, today announced the certification of the next generation of its YubiKey 5 FIPS Series – now FIPS 140-3 validated with Certificate #5291. Published by the National Institute of Standards and Technology (NIST), this milestone represents the latest evolution in cryptographic module validation and r...

LYON, France--(BUSINESS WIRE)--MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET) visant à améliorer la survie, annonce aujourd’hui un point sur ses activités et sa position de trésorerie au 31 mars 2026. « Au cours du premier trimestre 2026, nous avons poursuivi nos activités avec rigueur financière tout en soutenant l’avancement de nos priorités cliniques e...